Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisy Yang

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Journal of Antimicrobial Chemotherapy|April 10, 2015
The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortalityEmily Wang, Dimitrios Farmakiotis, Daisy Yang, et al.
Journal of Medical Economics|November 26, 2025
Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United StatesJason Shafrin, Kejal Jadhav, Cheryl Warren, et al.
Cancer Medicine|December 10, 2014
A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer CenterKhanh Vu, Nhiem V Luong, Julie Hubbard, et al.
Leukemia Research|September 12, 2025
Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemiaEhab L Atallah, Islam Sadek, David Wei, et al.
Future Oncology (London, England)|October 10, 2024
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trialEhab L Atallah, Michael J Mauro, Koji Sasaki, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid LeukemiaKathryn E Flynn, Joan Clements, Karen DeMairo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors - Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) StudyKathryn E Flynn, Joan Clements, Karen DeMairo, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Antimicrobial Chemotherapy|April 10, 2015
The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortalityEmily Wang, Dimitrios Farmakiotis, Daisy Yang, et al.
Journal of Medical Economics|November 26, 2025
Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United StatesJason Shafrin, Kejal Jadhav, Cheryl Warren, et al.
Cancer Medicine|December 10, 2014
A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer CenterKhanh Vu, Nhiem V Luong, Julie Hubbard, et al.
Leukemia Research|September 12, 2025
Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemiaEhab L Atallah, Islam Sadek, David Wei, et al.
Future Oncology (London, England)|October 10, 2024
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trialEhab L Atallah, Michael J Mauro, Koji Sasaki, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid LeukemiaKathryn E Flynn, Joan Clements, Karen DeMairo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors - Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) StudyKathryn E Flynn, Joan Clements, Karen DeMairo, et al.
Pageof 2